U.S. Markets close in 2 hrs 29 mins
  • S&P 500

    3,690.22
    +23.50 (+0.64%)
     
  • Dow 30

    30,151.34
    +181.82 (+0.61%)
     
  • Nasdaq

    12,446.72
    +69.54 (+0.56%)
     
  • Russell 2000

    1,881.16
    +32.45 (+1.76%)
     
  • Crude Oil

    46.18
    +0.54 (+1.18%)
     
  • Gold

    1,839.40
    -1.70 (-0.09%)
     
  • Silver

    24.26
    +0.13 (+0.53%)
     
  • EUR/USD

    1.2155
    +0.0006 (+0.0486%)
     
  • 10-Yr Bond

    0.9660
    +0.0460 (+5.00%)
     
  • Vix

    20.85
    -0.43 (-2.02%)
     
  • GBP/USD

    1.3492
    +0.0039 (+0.2914%)
     
  • USD/JPY

    104.0720
    +0.2120 (+0.2041%)
     
  • BTC-USD

    18,984.62
    -272.96 (-1.42%)
     
  • CMC Crypto 200

    372.06
    -7.18 (-1.89%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020

G1 Therapeutics
·1 min read

RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2020 on Wednesday, November 4, 2020 at 4:30 p.m. ET.

The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 6634419. The live and archived webcast will be available on the Events & Presentations page of the G1 website.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com